Xi'an Faithful BioTech Co., Ltd. yog muag Tirzepatide Raw Powder. Thov koj xav tiv tauj peb yog tias koj muaj kev xav tau kev yuav khoom.
Xa koj Cov Lus Nug kom paub meej ntxiv, Nyem email:sales4@faithfulbio.com
I. Kev nkag siab hauv paus ntsiab lus: Cov yam ntxwv tshiab ntawm Molecular thiab Mechanism of Action of Tirzepatide
Tirzepatide yog lub ntiaj teb thawj zaug thiab tam sim no tsuas yog siv tshuaj kho mob GLP-1/GIP dual receptor co-agonist. Nws cov qauv tsim molecular thiab cov txheej txheem ntawm kev ua haujlwm sawv cev rau kev ua tiav hauv kev lag luam, teeb tsa tus qauv rau kev txhim kho cov khoom zoo sib xws.
1. Molecular Structure thiab Modification Technology
Structureally, Tirzepatide yog ib tug linear peptide compound tsim los ntawm 39 amino acids, nrog rau cov mis mos molecular C₁₈₇H₂₉₁N₄₅O₅₉. Nws cov amino acid sequence yog raws li tib neeg GIP (glucose-dependent insulinotropic peptide), khaws 9 homologous amino acids ntawm GIP thiab 10 amino acids qhia los ntawm GIP thiab GLP-1 (glucagon-zoo li peptide-1). Los ntawm kev hloov kho cov qauv, nws ua tiav ob lub hom phiaj ntawm qhov ntev - ua haujlwm ntev thiab ua haujlwm siab. Cov txheej txheem kev hloov kho tseem ceeb suav nrog ob yam: thawj zaug, alanine ntawm txoj haujlwm 8 yog hloov nrog -aminoisobutyric acid (Aib), zoo tiv thaiv kev degradation los ntawm dipeptidyl peptidase-4 (DPP-4) thiab prolonging cov khoom lub sijhawm ntawm kev ua hauv vivo; Thib ob, C-18 alkyl diacid sab saw txuas rau C-terminus, txhim kho cov khoom lag luam binding affinity rau plasma albumin.
Hais txog cov txheej txheem synthesis, Tirzepatide ntiav cov txheej txheem ua ke "khoom-theem synthesis + kua-theem splicing" txheej txheem. Ua ntej, plaub ntu peptide luv luv (AA1-14, AA15-21, AA22-29, thiab AA30-39) tau npaj siv cov khoom sib txuas ua ke, thiab tom qab ntawd cov khoom tawg yog txuas ua ke siv cov kua-theem synthesis los tsim cov khoom kawg. Piv nrog rau cov txheej txheem kev sib txuas ua ke ntawm tag nrho cov amino acids, cov txheej txheem no txo cov amino acid siv ntau dua 30%, txo qis impurity tsim tus nqi, thiab ib txhij txhim kho kev tsim khoom thiab cov khoom purity, tso lub hauv paus rau kev lag luam loj loj.
2. Dual-Lub Hom Phiaj Mechanism of Action thiab Synergistic Advantages
Cov txheej txheem tseem ceeb ntawm cov kab mob metabolic cuam tshuam nrog ntau yam, suav nrog insulin tsis kam, glucagon secretion disorders, thiab kev noj qab haus huv tsis txaus. Ib txwm ib txwm- cov khoom lag luam feem ntau tawm tsam kom ua tiav cov kev cai dav dav. Tirzepatide's revolutionary breakthrough nyob rau tib lub sij hawm ua kom muaj ob lub incretin receptors loj, GLP-1 thiab GIP, ua tiav ntau qhov kev txhim kho metabolic los ntawm kev sib koom ua ke.
GLP-1 receptor agonists tau ntev tau ua pov thawj muaj txiaj ntsig zoo hauv kev kho mob ntawm cov kab mob metabolic, ua tiav cov ntshav qab zib thiab poob phaus los ntawm kev txhawb nqa cov tshuaj insulin, inhibiting glucagon tso tawm, ncua kev ua pa ntawm plab, thiab txo qis hauv nruab nrab qab los noj mov. GIP, lwm qhov tseem ceeb incretin, tuaj yeem txhawb nqa cov tshuaj insulin tso tawm thiab tswj cov lipid metabolism hauv cov tib neeg noj qab haus huv, tab sis nws cov haujlwm tau txo qis hauv cov neeg mob ntshav qab zib hom 2. Tirzepatide, los ntawm kev ua kom cov GIP receptors tsis tuaj yeem tsuas yog rov ua kom lub cev muaj zog ntawm GIP hauv cov neeg mob, tab sis kuj ua rau muaj kev sib koom ua ke nrog kev ua haujlwm ntawm GLP-1 receptors: ntawm ib sab, nws txhim kho qhov rhiab heev thiab kev ruaj khov ntawm insulin secretion, ua tiav cov ntshav qab zib kom ruaj khov; ntawm qhov tod tes, nws accelerates rog tawg thiab siv zog, txhim kho qhov hnyav; tib lub sijhawm, nws tuaj yeem txhim kho vascular endothelial muaj nuj nqi thiab txo qhov kev pheej hmoo ntawm cov kab mob plawv.
Xa koj Cov Lus Nug kom paub meej ntxiv, Nyem email:sales4@faithfulbio.com
II. Kev Tshawb Fawb thiab Kev Ua Lag Luam: Ib Xyoo Xyoo- Kev Mus Los Ntev los ntawm Kev Tshawb Fawb Txog Kev Tshaj Tawm rau Ntiaj Teb
1. Cov ntsiab lus tseem ceeb R & D
Txoj kev loj hlob ntawm Tirzepatide tau pib xyoo 2010. Raws li nyob rau hauv - kev tshawb fawb tob rau hauv txoj hauv kev incretin signaling, cov kws tshawb fawb tau npaj lub tswv yim tshiab ntawm "dual-target synergistic regulation," breaking through the effective bottleneck of single-target products. Los ntawm 2010 mus rau 2015, pab neeg R&D tau ua tiav cov qauv tsim qauv, kev ua kom zoo ntawm cov qauv, thiab ua ntej- kev tshawb fawb soj ntsuam, daws cov teeb meem xaiv ntawm dual- lub hom phiaj ua kom thiab lees paub cov khoom muaj kev nyab xeeb thiab ua tau zoo. Hauv xyoo 2016, Tirzepatide tau nkag mus rau theem kho mob, pib SURPASS series ntawm kev sim thoob ntiaj teb ntau qhov chaw kuaj mob, suav nrog 12,000 tus neeg mob ntshav qab zib hom 2 hauv ntau lub tebchaws thiab cheeb tsam thoob ntiaj teb, ntsuas ntsuas nws cov txiaj ntsig glycemic, kev nyab xeeb, thiab cov txiaj ntsig ntawm lub plawv. Xyoo 2021, cov txiaj ntsig ntawm SURPASS series sim tau raug tso tawm, qhia tias nws qhov txo qis HbA1c mus txog 2.0%-2.5%, nrog rau qhov hnyav hnyav, thaum tseem ua rau pom kev nyab xeeb ntawm lub plawv zoo, tso lub hauv paus tseem ceeb rau kev pom zoo tom qab.
Hauv kev pom zoo thiab kev tsim khoom lag luam, Tirzepatide nthuav tawm kev nce qib sai: Lub Tsib Hlis 2022, US FDA thawj zaug pom zoo rau kev kho mob ntshav qab zib hom 2; Lub Kaum Ib Hlis 2023, FDA pom zoo rau kev rog rog; Nyob rau lub Tsib Hlis 2024, Tuam Tshoj National Medical Products Administration (NMPA) tau pom zoo rau cov ntshav qab zib, thiab thaum Lub Xya Hli ntawm tib lub xyoo, nws tau nthuav dav suav nrog kev rog rog, tus nqi ntawm 890 yuan ib vial (1.5mg), tau nkag mus rau Suav lag luam; Thaum kawg ntawm 2025, Tirzepatide tau raug pom zoo nyob rau hauv ntau tshaj 100 lub teb chaws thiab cheeb tsam thoob ntiaj teb, npog ob lub ntsiab lus qhia txog ntshav qab zib thiab rog, dhau los ua ib qho ntawm cov khoom tseem ceeb hauv kev kho kab mob metabolic thoob ntiaj teb.
III. Cov qauv kev lag luam: Kev loj hlob tawg thiab kev sib tw Duopoly
Txij li thaum nws tso tawm, Tirzepatide tau ua tiav kev lag luam loj hlob vim nws cov txiaj ntsig zoo thiab cov lus qhia dav dav, sai sai dhau los ua cov nyiaj tau los tseem ceeb rau lub tuam txhab. Nws kuj tau tsim ib tug duopoly nrog Semaglutide, dominating txoj kev loj hlob kev taw qhia ntawm lub ntiaj teb no GLP-1 khoom lag luam.
1. Kev Ua Lag Luam Thoob Ntiaj Teb: Ib qho Blockbuster
Tirzepatide kev ua lag luam kev ua lag luam tau tsim ib qho txuj ci tseem ceeb ntawm kev loj hlob rau cov khoom lag luam tshiab txij li thaum nws pib. Hauv nws thawj xyoo ntawm kev ua lag luam hauv 2022, nws qhov kev muag khoom thoob ntiaj teb tau txog $ 5.339 billion, deb tshaj thawj - xyoo muag khoom ntawm lwm yam khoom tshiab nyob rau tib lub sijhawm; xyoo 2023, kev muag khoom tau tshaj $ 10 nphom, nce mus txog $ 10.85 billion; thiab nyob rau xyoo 2024, nws tau ua tiav qhov kev loj hlob sai, nrog kev muag khoom thoob ntiaj teb txog $ 16.4458 billion, ntawm cov suab thaj - txo qis muag $ 11.5401 billion thiab qhov hnyav- poob version muag $ 4.9257 billion, suav txog 36% ntawm lub tuam txhab cov nyiaj tau los tag nrho, ua rau nws yog ib qho ntawm cov khoom lag luam thoob ntiaj teb.
Hais txog kev faib khoom hauv cheeb tsam, North America yog Tirzepatide lub lag luam tseem ceeb, suav txog 65% ntawm kev muag khoom thoob ntiaj teb (feem ntau yog Tebchaws Meskas), feem ntau yog vim nws txoj kev them nyiaj kho mob laus thiab cov neeg mob loj nrog cov kab mob metabolic. Kev lag luam nyob sab Europe suav txog kwv yees li 20%, qhia kev loj hlob tsis tu ncua. Thaum Suav lag luam pib tom qab (teev npe hauv 2024), nws tau pom qhov kev loj hlob sai tshaj plaws, nrog rau kev loj hlob txhua xyoo ntawm 45%. Hauv xyoo 2024, kev muag khoom hauv Suav lag luam tau tshaj $ 1.5 nphom, dhau los ua ib lub tshuab tseem ceeb ntawm kev loj hlob thoob ntiaj teb. Hauv thawj peb lub hlis twg ntawm 2025, Tirzepatide qhov muag thoob ntiaj teb tau mus txog $ 24.837 billion, kwv yees li ntawm Semaglutide. Raws li Bloomberg qhov kev kwv yees, Tirzepatide yuav dhau Semaglutide hauv 2026, ua tiav kev muag khoom ntawm $ 40.8 billion, thiab qhov sib txawv yuav txuas ntxiv mus ntxiv, nrog rau kev muag khoom yuav ncav cuag $ 56.8 nphom los ntawm 2029, ua kom nws yog "tus huab tais ntiaj teb."
2. Kev Sib Tw Sib Tw: Duopoly Dominates Thaum Kev Sib Tw Tshuaj Yeeb Yam
Lub ntiaj teb no GLP tam sim no-1 cov khoom lag luam yog tus cwj pwm los ntawm duopoly, nrog Tirzepatide thiab Semaglutide ua ke tuav 88% ntawm kev lag luam thoob ntiaj teb, ua rau nws nyuaj rau lwm lub tuam txhab los tawm tsam lawv txoj haujlwm. Kev sib tw tseem ceeb ntawm ob cov khoom lag luam tsom rau plaub qhov loj: kev ua tau zoo, kev qhia, nqe, thiab kev faib tawm. Hais txog kev ua tau zoo, Tirzepatide yog me ntsis zoo dua Semaglutide hais txog kev poob phaus thiab kev tiv thaiv kab mob plawv, tab sis Semaglutide muaj qhov tseem ceeb ua ntej -mover kom zoo dua. Hais txog cov lus qhia, ob qho tib si npog ntshav qab zib thiab rog, tab sis Tirzepatide tau ua tiav sai dua hauv cov kev qhia muaj peev xwm xws li obstructive pw tsaug zog apnea (OSA) thiab lub plawv tsis ua hauj lwm nrog khaws cia ejection feem (HFpEF). Hais txog tus nqi, nrog rau suav nrog hauv Tuam Tshoj txoj kev pov hwm kho mob, Tirzepatide tus nqi tau txo qis, nrog qee qhov tshwj xeeb ua ntej- muag rau qis li 450 yuan, maj mam txo tus nqi sib txawv nrog Semaglutide. Nyob rau hauv cov nqe lus ntawm kev faib tawm, ob qho tib si ua kom lawv nthuav dav rau hauv online platforms (Meituan, JD.com, thiab lwm yam) los txhim kho cov khoom siv tau los ntawm O2O qauv. Tirzepatide qhov kev txiav txim hauv online ntim tau nce ntau tshaj kaum npaug ntawm lub hlis-rau-hli tom qab tus nqi txo, ua rau pom muaj zog elasticity.
Dhau li ntawm kev sib tw ncaj qha nrog Semaglutide, Tirzepatide tseem yuav ntsib cov teeb meem los ntawm cov khoom lag luam thiab biosimilar yav tom ntej. Los ntawm txoj kev xav patent, Tirzepatide's US patent tiv thaiv tas sij hawm hauv 2036, thiab nws txoj kev tiv thaiv Suav patent yuav tas rau xyoo 2035, ua rau nws cov patent barrier muaj zog dua piv rau Semaglutide (uas Suav patent tas sij hawm hauv 2026). Txawm li cas los xij, ntau lub tuam txhab thoob ntiaj teb tau pib tsim cov qauv ntawm Tirzepatide, thiab tus nqi ntawm cov khoom lag luam no tuaj yeem poob mus rau 20% ntawm tus nqi qub, cuam tshuam rau cov khoom lag luam qub. Tsis tas li ntawd, kev txhim kho ntau yam -cov khoom lag luam (xws li GLP-1/GIP/GCGR tri-cov phiaj xwm agonists) tau nrawm dua, nrog rau qee cov khoom sib tw twb tau qhia txog qhov poob phaus los ze rau cov Tirzepatide, muaj peev xwm hloov kho kev lag luam kev sib tw toj roob hauv pes.
Xaus
Tirzepatide txoj kev vam meej tsis yog nyob rau hauv nws qhov kev ua tau zoo hauv kev kho mob nkaus xwb tab sis kuj tseem nyob hauv nws cov pioneering dual - lub hom phiaj ntawm kev ua, muab cov kev daws teeb meem tshiab rau kev kho cov kab mob metabolic thiab coj mus rau lub sijhawm tshiab ntawm "dual-target/multi-target agonists." Los ntawm kev xav txog kev lag luam tus nqi, Tirzepatide tsis tau tsuas yog ua rau muaj kev loj hlob tawg hauv GLP-1 cov khoom lag luam tab sis kuj txhawb kev hloov kho tshiab hauv peptide synthesis thiab formulation technologies, txhawb kev txhim kho thiab kev loj hlob ntawm kev lag luam saw thiab ua rau muaj txiaj ntsig zoo rau kev tiv thaiv thoob ntiaj teb thiab tswj cov kab mob metabolic.
Nyob rau hauv lub neej yav tom ntej, nrog kev nthuav dav ntawm kev qhia, kev hloov kho thev naus laus zis tsis tu ncua, thiab nkag mus rau hauv cov lag luam tawm tshiab, Tirzepatide xav tias yuav tswj hwm nws txoj kev ua lag luam thiab dhau los ua ib lub ntiaj teb siab tshaj - muag cov khoom tshiab. Txawm li cas los xij, nws tseem yuav ntsib ntau yam kev sib tw, suav nrog txoj cai tswjfwm, kev sib tw ua lag luam, thiab kev lag luam kev lag luam hloov pauv, xav kom cov tuam txhab cuam tshuam los daws cov teeb meem no los ntawm kev tsim kho thev naus laus zis, kev tswj hwm tus nqi, thiab kev ua kom zoo dua channel. Rau cov kws kho mob hauv kev lag luam, Tirzepatide txoj kev txhim kho txoj kev loj hlob muaj txiaj ntsig zoo rau kev tshawb fawb cov khoom tshiab thiab kev tsim kho thiab kev lag luam, thiab nws cov kev txhim kho yav tom ntej yuav muab cov ntaub ntawv tseem ceeb rau kev lag luam layout, tsav tsheb mus tas li hauv ntiaj teb kev kho kab mob metabolic.
Raws li tus neeg muab kev pabcuam zoo tshaj plaws Tirzepatide CAS 2023788-19-2, Xi'an Faithful BioTech Co., Ltd. leverages xeev- ntawm- the-art technology production and rigorous quality assurance to as international pharmaceutical requirements. Peb txoj kev mob siab rau kev ua tau zoo tshaj plaws, tus nqi tsim nyog, thiab kev txhawb nqa kev tsim kho tau ua rau peb nyiam koom tes rau cov kws kho mob thiab cov kws tshawb fawb thoob ntiaj teb. Txhawm rau kom tau txais cov ncauj lus qhia ntxaws ntxaws thiab daim ntawv thov kev taw qhia rau peb Tirzepatide Powder, hu rau peb pab neeg ua haujlwm ntawmsales4@faithfulbio.comthiab tshawb xyuas seb peb cov khoom tuaj yeem txhim kho koj cov khoom tsim li cas.